Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRS-207 + Pembrolizumab in Advanced Gastric/GEJ/Esophageal Cancer
NCT03122548Phase 2Terminated
- Sponsor
- Aduro Biotech, Inc.
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Oncolytic Viruses, Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CRS-207 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Aduro Biotech, Inc. Primary endpoint: Objective Response Rate at 15 weeks. Started Aug 2017; status: terminated.
02
Drugs
CRS-207
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT03122548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122548.